The funding agreement with ENISA of 450,000 Euros was designed to complete the plant with more technical equipment, with the objective of enhancing 3P Biopharmaceuticals’ productivity and competitiveness.

3P Biopharmaceuticals, a biotechnology company dedicated to the development of biologicals and cell therapy products has obtained the funding for 450,000 Euros with ENISA, the National Company of Innovation.